During Monday’s Current trade, Shares of Constellation Brands, Inc. (NYSE:STZ), lost -1.12% to $128.38.
Constellation Brands, Inc. (STZ), a leading beverage alcohol company, declared it will report financial results for its fiscal second quarter ended Aug. 31, 2015, on Wed., Oct. 7, 2015, before the open of the U.S. markets. A conference call to talk about the financial results and outlook will be hosted by President and Chief Executive Officer Rob Sands and Executive Vice President and Chief Financial Officer David Klein at 10:30 a.m. eastern time, Oct. 7, 2015.
Constellation Brands, Inc., together with its auxiliaries, produces, imports, and markets beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy. The company sells wine across various categories, counting table wine, sparkling wine, and dessert wine.
Shares of GameStop Corp. (NYSE:GME), declined -0.61% to $40.77, during its current trading session.
GameStop, a family of specialty retail brands that makes the most popular technologies affordable and simple, recently declared that customers can start using Android Pay to pay for purchases in its more than 4,200 U.S. video game stores.
GameStop has accomplished a nationwide rollout of Android Pay, which uses the NFC (Near Field Communication) feature on mobile devices to allow users to transform mobile payments with an easy and secure way to pay.
GameStop shoppers will find it easier than ever to purchase the latest games, consoles, accessories, and electronics during a quick stop to their favorite video game store.
With Android Pay, customers can pay with their credit or debit card, across multiple Android devices, by simply unlocking their device, placing it near the contactless terminal, and waiting for their device to beep or vibrate to show payment was made.
GameStop Corp. operates as a multichannel video game retailer. It sells new and pre-owned video game hardware; physical and digital video game software; pre-owned and value video game products; video game accessories, such as controllers, gaming headsets, memory cards, and other add-ons for use with video game hardware and software; and digital products, counting downloadable content, network points cards, prepaid digital and online timecards, and digitally downloadable software.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), during its Monday’s current trading session decreased -4.59% to $79.88.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators declared recently new results from the company’s ongoing Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis) patients with familial amyloidotic polyneuropathy (FAP). In partnershipwith investigators at The Scripps Research Institute and Misfolding Diagnostics, Inc., patisiran administration was shown to reduce pathogenic, misfolded TTR monomers and oligomers in FAP patients in the Phase 2 OLE study. Specifically, patisiran administration resulted in a rapid and sustained reduction of about 90% in serum non-native conformations of TTR (NNTTR). Since NNTTR is pathogenic in ATTR amyloidosis, these results provide direct mechanistic evidence supporting the therapeutic hypothesis that TTR knockdown has the potential to result in clinical benefit. In addition, Alnylam presented complete 12-month data from all 27 patients initially enrolled in the patisiran OLE study, showing a mean 3.1-point decrease in the modified Neuropathy Impairment Score (mNIS+7) at 12 months in addition to sustained mean maximum reductions in total serum TTR of 91% for over 18 months. Moreover, patisiran administration was found to be generally well tolerated out to 21 months of treatment.
Alnylam’s ongoing Phase 2 OLE study is an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of patisiran administration in FAP patients that were formerly enrolled in a Phase 2 study. Patisiran is being administered once every 3 weeks at a dose of 0.3 mg/kg by intravenous infusion. The study is measuring a number of clinical endpoints every six months, counting mNIS+7 which is an evaluation of muscle weakness, sensory and autonomic function, and nerve conductance, where neuropathy progression leads to an raised score over time. The change in the mNIS+7 measurement from baseline to 18 months is the primary endpoint in the company’s ongoing Phase 3 APOLLO trial of patisiran in FAP patients.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia. I
Finally, Harris Corporation (NYSE:HRS), decreased -1.44%, to $71.18.
Harris Corporation (HRS) has received a $21 million order from a Latin American nation for Falcon III® tactical radios that will be used to establish high data rate netoperates as part of a military communications modernization program.
The order comprises manpack, vehicular and base configurations of the Harris RF-7800H wideband tactical radio, which delivers expanded data capabilities in long-range, beyond-line-of-sight environments. The radio transmits voice, images and other larger data files over thousands of kilometers.
The nation also is acquiring handheld and vehicular configurations of the Harris RF-7850M multiband networking radio – the first international radio to simultaneously support wideband communications, mobile ad-hoc networking, and legacy narrowband waveforms.
Harris Corporation provides technology-based solutions that solve government and commercial customers mission-critical challenges. The company operates in four segments: Communication Systems, Critical Netoperates, Electronic Systems, and Space and Intelligence Systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
